Successful long-term control of lymphomatous meningitis with intraventricular rituximab

[1]  M. Weller,et al.  Pathogenesis and management of primary CNS lymphoma , 2012, Expert review of anticancer therapy.

[2]  R. Advani,et al.  Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. , 2011, Blood.

[3]  K. Hoang-Xuan,et al.  Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  J. Fridlyand,et al.  Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Fimmers,et al.  Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Thall,et al.  Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab , 2002, Journal of Neuro-Oncology.

[7]  A. Patchefsky,et al.  Case report 3 , 1976, Skeletal Radiology.

[8]  I. Schmidt-Wolf,et al.  Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. , 2004, Haematologica.